SCHEMBL24379875

SCHEMBL24379875

CCCCOC(=O)COCCOCCOCCOCCOCC(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAAA Q02083 1/20 0.47
ALDH1A1 P00352 4/20 0.47
ATM Q13315 1/20 0.44
DGKA P23743 1/20 0.42
MGAM O43451 1/20 0.41
GAA P10253 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
TSHR P16473 3/20 0.41
HPGD P15428 2/20 0.41
CES2 O00748 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RAD52 P43351 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FAAH O00519 1/20 0.40
HCAR2 Q8TDS4 1/20 0.39
TRPA1 O75762 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL272386 0.94 CES2 (0.47) NAAAALDH1A1ATMDGKAMGAM
SCHEMBL7652075 0.94 ALDH1A1 (0.52) NAAAALDH1A1ATMDGKATSHR
SCHEMBL546058 0.90 CES2 (0.50) NAAAALDH1A1ATMDGKAMGAM
SCHEMBL6317486 0.88 CES2 (0.48) NAAAALDH1A1ATMDGKAMGAM
SCHEMBL28100737 0.88 DGKA (0.50) NAAAALDH1A1ATMDGKATSHR
SCHEMBL18612049 0.88 ALDH1A1 (0.50) NAAAALDH1A1ATMDGKATSHR
SCHEMBL18470078 0.88 DGKA (0.50) NAAAALDH1A1ATMDGKATSHR
SCHEMBL1055702 0.88 ALDH1A1 (0.54) NAAAALDH1A1ATMDGKATSHR
SCHEMBL6665142 0.88 GAA (0.52) ALDH1A1MGAMGAASIMGAM2
Ethyl Acetate SCHEMBL22471908 0.87 ALDH1A1 (0.52) NAAAALDH1A1ATMDGKAMGAM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 NAAA 1342/4885ALDH1A1 2776/4885ATM 194/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 NAAA 1342/4885ALDH1A1 2776/4885ATM 194/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 NAAA 1342/4885ALDH1A1 2776/4885ATM 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.